AstraZeneca

AZN · NYSE · USD

$156.90−0.51%−$0.80

Close · October 2, 2026

At a glance

Revenue growth: +8.63%; 2025 vs 2024
Net income growth: +45.34%; 2025 vs 2024
Net margin: 17.4%; 2024: 13.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total assets	114,074	104,035	101,119	96,483	105,363	66,729	61,377	60,651	63,354	62,526
Current assets	28,723	25,827	25,054	22,593	26,244	19,544	15,563	15,591	13,150	13,262
Cash and equivalents	5,711	5,488	5,840	6,166	6,329	7,832	5,369	4,831	3,324	5,018
Short-term investments	8.0	37.0	20.0	64.0	53.0	42.0	38.0	40.0	1,230	884
Receivables	14,301	13,094	11,935	9,923	8,795	5,651	5,181	4,837	4,452	4,764
Inventory	6,557	5,288	5,424	4,699	8,983	4,024	3,193	2,890	3,035	2,334
Net property, plant and equipment	14,703	11,647	10,502	9,449	10,171	8,917	8,335	7,421	7,615	6,848
Goodwill	21,242	21,025	20,048	19,820	19,997	11,845	11,668	11,707	11,825	11,658
Other intangible assets	37,846	37,177	38,089	39,307	42,387	20,947	20,833	21,959	26,188	27,586
Long-term investments	2,525	1,900	1,677	1,142	1,262	1,192	1,512	978	1,120	891
Current liabilities	30,617	27,866	30,542	26,293	22,594	20,307	18,117	16,292	16,383	15,256
Accounts payable	3,820	3,640	3,267	2,550	2,824	2,350	1,774	1,720	2,285	1,680
Long-term debt	24,715	26,621	22,403	23,908	29,717	19,804	17,894	19,201	17,387	16,513
Total debt	29,059	30,130	29,134	30,785	32,952	22,051	20,202	20,227	18,813	18,393
Total liabilities	65,355	63,164	61,953	59,425	66,076	51,091	46,781	46,607	46,712	45,857
Total equity (incl. minority)	48,719	40,871	39,166	37,058	39,287	15,638	14,596	14,044	16,642	16,669
Retained earnings	12,599	7,229	4,516	3,120	3,644	6,442	5,001	7,690	9,238	10,088
Minority interest	52.0	85.0	23.0	21.0	19.0	16.0	1,469	1,576	1,682	1,815